Abstract
The clinical efficacy and safety of a four-drug combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone was assessed for patients with relapsed or refractory multiple myeloma. Seventy patients received at least two cycles of treatment with bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8, and 11; cyclophosphamide 150 mg/m(2) orally on days 1-4; thalidomide 50 mg/day orally every day; and dexamethasone 20 mg/m(2) intravenously on days 1, 4, 8, and 11. The overall best response rate was 88%, with 46% complete response, 9% very good partial response, and 33% partial response. After a median follow-up of 12.6 months, the median progression-free survival (PFS) was 14.6 months with a 3-year PFS of 14% and the median overall survival (OS) was 31.6 months with a 3-year OS of 47%. Grade 3 or 4 adverse events included thrombocytopenia (12%), neutropenia (4%), peripheral sensory neuropathy (3%), with thrombosis being very rare (<1%). Bortezomib combined with cyclophosphamide, thalidomide, and dexamethasone is a highly effective salvage therapy with manageable toxicity for patients with relapsed or refractory multiple myeloma.
References
Feb 1, 1990·American Journal of Hematology·R AlexanianS Tucker
Oct 14, 1989·Lancet·D SamsonM Hamon
Oct 23, 1997·British Journal of Haematology·H GoldschmidtR Haas
Dec 3, 1999·British Journal of Haematology·B SirohiJ Treleaven
Aug 28, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosN Anagnostopoulos
Apr 18, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·Ramón García-SanzJesús Fernando San Miguel
Jan 7, 2003·Medical Oncology·Gordan SrkalovicMohamad A Hussein
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Mar 20, 2004·Lancet·Bhawna Sirohi, Ray Powles
Oct 6, 2004·British Journal of Haematology·S JagannathK C Anderson
Oct 29, 2004·The New England Journal of Medicine·Robert A Kyle, S Vincent Rajkumar
Jun 15, 2005·British Journal of Haematology·Heather E OakerveeJamie D Cavenagh
Aug 23, 2005·Leukemia Research·Pellegrino MustoAntonio Palumbo
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul G RichardsonAnthony A Amato
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Dec 7, 2006·Blood·Antonio PalumboUNKNOWN Gruppo Italiano Malattie Ematologicche dell'Adulto
Mar 6, 2007·Journal of the National Comprehensive Cancer Network : JNCCN·Paul G RichardsonKenneth C Anderson
Aug 11, 2007·Blood·Paul G RichardsonKenneth C Anderson
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Nov 23, 2007·The New England Journal of Medicine·Donna M WeberUNKNOWN Multiple Myeloma (009) Study Investigators
Jul 23, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna E ReeceA Keith Stewart
Aug 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asher Chanan-KhanPaul G Richardson
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Sep 5, 2008·Leukemia·E TerposM A Dimopoulos
Feb 3, 2009·British Journal of Haematology·Rakesh PopatJamie Cavenagh
Citations
Nov 19, 2013·Annals of Hematology·Silvia ParkKihyun Kim
Nov 28, 2012·Leukemia Research·Heinz Ludwig, Peter Sonneveld
Nov 26, 2013·Blood Cancer Journal·M OffidaniP Leoni
Apr 9, 2011·Case Reports in Oncology·Soo-Young BaeJe-Jung Lee
Jan 18, 2011·Hematology·Nina Shah, Sagar Lonial
Sep 13, 2014·Hematology/oncology Clinics of North America·Silvia Gentili, Sagar Lonial
Dec 23, 2014·BioMed Research International·Jae-Sook AhnJe-Jung Lee
Jun 15, 2010·International Journal of Hematology·Jae Hoon LeeUNKNOWN Korean Multiple Myeloma Working Party
Jan 29, 2013·International Journal of Hematology·Sung-Hoon JungJe-Jung Lee
Mar 26, 2011·Annals of Hematology·Massimo OffidaniPietro Leoni
Feb 9, 2012·Annals of Hematology·Jae-Sook AhnUNKNOWN Korean Multiple Myeloma Working Party (KMMWP)
Dec 30, 2015·Leukemia·J LaubachP G Richardson
Apr 8, 2011·Expert Opinion on Investigational Drugs·Massimo OffidaniAntonio Palumbo
Jun 29, 2012·Seminars in Hematology·Philippe Moreau
Feb 26, 2011·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·R Schots
Sep 25, 2010·Cancer Treatment Reviews·Niels W C J van de DonkAntonio Palumbo
Jan 9, 2013·British Journal of Haematology·Maria T PetrucciJoan Bladé
Mar 19, 2014·Clinical Lymphoma, Myeloma & Leukemia·Jae-Sook AhnJe-Jung Lee
Dec 31, 2011·Clinical Lymphoma, Myeloma & Leukemia·Gerrard TeohYeo-Kyeoung Kim
Aug 7, 2010·Blood·A Keith Stewart
May 28, 2014·Leukemia Research·Adam Walter-CroneckAnna Dmoszynska
Jun 29, 2012·Seminars in Hematology·Andrzej Jakubowiak
May 17, 2018·Expert Review of Anticancer Therapy·Giusy CetaniStefania Oliva
Jul 22, 2018·European Journal of Haematology·Evangelos TerposMeletios A Dimopoulos
Apr 17, 2013·Blood Research·Jae-Sook AhnJe-Jung Lee
Feb 20, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Ali McBrideKeith Stockerl-Goldstein
Nov 14, 2012·Expert Review of Hematology·Ajay Nooka, Sagar Lonial
Jun 20, 2017·Hematological Oncology·Shang-Yi HuangYa-Wen Yang
Jan 31, 2019·Health Science Reports·Cyrille HulinMichel Delforge
Sep 9, 2016·The Korean Journal of Internal Medicine·Junshik Hong, Jae Hoon Lee